SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins the later rounds of HAX and IndieBio graduates.  HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

SOSV

HAX is a venture capital-based program dedicated to accelerating startups with a hardware element. Their program operates across two locations, San Francisco and Shenzhen, giving founders the resources necessary to move with lightning speed. Teams accepted into the program will focus on rapid iteration of prototyping in many forms. This includes physical models, technology iterations, user interaction studies, volumetric studies, marketing messaging, business plans and launch strategies. With the help of HAX’s full-time staff, mentors, partners, and startup community, they’ll also work with you on developing a scalable business plan. As teams are ready to take their  product to market, they’ll head to San Francisco to work with HAX on business development, fundraising, and growth. This stage emphasizes introductions to corporates, investors, partners and press. It also focuses on helping teams secure their first round of funding, as well as gain first-revenue and partnership traction. HAX is an SOSV program. SOSV is a global venture capital firm that operates startup venture programs around the world. SOSV had more than 1,000 portfolio companies and $950 million in assets under management.

We're Acequia Capital, a team and partnership with roots in Albuquerque. We're knowledge workers and systems thinkers who love to keep good company in most fields.

Acequia Capital (AceCap)

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

Marinya Capital is the family office of a branch of the Fairfax family. It was originally established by Fairfax media, a large Australian media company. Marinya holds active property investments and a portfolio of investments into fund managers. Marinya Capital also makes direct private equity and venture capital investments into select opportunities.

Marinya Capital

CULT Food Science is an investment company focused on supporting and advancing the technology behind the future of food. It identifies and makes equity investments in global cultivated meat and dairy companies that are developing and commercializing innovative food technologies that enable a kinder, more secure, and more sustainable food supply chain.

Cult Food Science

C3 is investing in early-stage climate-impact startups.

Unruly is a new investment firm, aiming to find and fund the best founders building the most innovative companies at the frontiers of what's possible today. We invest early, are not scared of risky moonshots and become your biggest fans.

Unruly Capital

Unicorn Biotechnologies

Unicorn Biotechnologies is developing a next-generation biomanufacturing platform to power the cell-based manufacturing revolution, starting with cultivated meat. By providing a clear path to affordably and rapidly scale cultivated meat, we will improve human and planetary health and drive the transition to animal-free agriculture.

Unicorn Biotechnologies is a UK-based startup that specializes in novel bioreactor solutions. According to the company, its bioreactors provide fully automated seeding, passaging, perfusion, differentiation, and harvesting workflows and support all cell types. Further, it uses AI for real-time control and monitoring and provides actionable insights for process optimizations.

Making meat sustainable over the long term

Cell-cultured Meat

CULT Food Science Venture Arm Company Unicorn Biotechnologies Launches Non-GMO Cell Line & Announces Commercial Partnership

Unicorn Biotechnologies is a UK-based startup that specializes in novel bioreactor solutions. According to the company, its bioreactors provide fully automated seeding, passaging, perfusion, differentiation, and harvesting workflows and support all cell types. Further, it uses AI for real-time control and monitoring and provides actionable insights for process optimizations.Funding and financialsIn <a href="https://sp-edge.com/updates/9898">April 2022</a>, Unicorn Biotechnologies raised USD 3.2 million in an oversubscribed seed funding round led by Acequia Capital. The funding was earmarked for commercialization, R&amp;D, and expansion efforts.

Mosa Meat is a Dutch cell-cultured meat startup founded by Dr. Mark Post of Maastricht University, and was the first-ever company to produce a lab-grown meat burger. The startup produces meat by growing myosatellite cells (muscle stem cells) extracted from an animal in a bioreactor fed with a nutrient-dense medium.The company replaced the fetal bovine serum (FBS) from its growth medium in July 2020, which led to an 88x cost reduction in its medium. As of March 2024, Mosa Meat operated the Center for Advanced Meat Production, Upscaling, and Sustainability (CAMPUS), a facility spanning over 79,000 sq ft that was designed to be expandable as demand grows.In <a href="https://sp-edge.com/updates/21645">September 2023</a>, Mosa Meat became the first cultivated meat company to attain B Corp certification. The company also announced plans to apply for regulatory approval in countries worldwide. In <a href="https://sp-edge.com/updates/21645">September 2023</a>, Mosa Meat became the first cultivated meat company to attain B Corp certification. The company also announced plans to apply for regulatory approval in countries worldwide. In <a href="https://sp-edge.com/updates/31970">July 2024</a>, it conducted the first official tasting of its cultivated beef product, the Mosa Burger, in the Netherlands. This event gathered Dutch cattle farmers, food product developers, and industry representatives to collect expert feedback.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/14175">November 2022</a>, Mosa Meat entered into an agreement with Singapore-based contract development and manufacturing organization (CDMO) Esco Aster to commercialize its cultivated beef in Singapore. Further, in <a href="https://sp-edge.com/updates/16845">March 2023</a>, the company partnered withNutreco to develop a cell feed supply chain that can expedite production and scalability while reducing cost.Funding and financialsIn its latest funding round in <a href="https://sp-edge.com/updates/28536">April 2024</a>, the company raised EUR 40 million (~USD 42.5 million) in an oversubscribed funding round co-led by Lowercarbon Capital and M Ventures, with participation from PHW Group, Invest-NL, LIOF, and LEF. The funds were earmarked for scaling production procedures, reducing production costs, and gearing up for commercialization.

Mosa Meat

SuperMeat is a cellular agriculture startup developing cultured chicken meat. The company uses chicken cells and claims to grow them in a culture medium free from antibiotics and contaminants to develop its products. SuperMeat also operates a test kitchen known as The Chicken. It is claimed to be the world’s first farm-to-fork facility where diners can observe the production of cultivated chicken.In <a href="https://sp-edge.com/updates/21733">September 2023</a>, The Orthodox Union (OU) certified SuperMeat’s cultivated chicken as “kosher.” Further, the OU and SuperMeat will collaborate on establishing guidelines for the industry.In&nbsp;<a href="https://sp-edge.com/updates/35765">November 2024</a>, the company announced it had achieved cost parity for its cultivated chicken and could produce it at at USD 11.79 per pound at scale, matching the price of premium US pasture-raised chicken.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/9319">March 2022</a>, SuperMeat signed an MoU with PHW to supply cultivated meat products including chicken, turkey, and duck to the European market. The company also <a href="https://sp-edge.com/updates/8997">partnered</a> with Ajinomoto to set up a joint venture to accelerate the commercialization of cultivated meat while focusing on developing a cost-competitive cell growth media.In <a href="https://sp-edge.com/updates/11867">July 2022</a>, the company signed an MoU with Switzerland’s largest retail supermarket chain and leading meat manufacturer, Migros to expedite production and distribution of cultured meat at a commercial scale with a focus on European markets.&nbsp;

SuperMeat

Uncommon (formerly HigherSteaks) is a UK-based cell-cultured meat startup that uses cellular agriculture to grow pork from animal cells. The company leverages cellular agriculture and in-house developed RNA technologies to cultivate meat and claims its technology eliminates the need for genetic engineering and growth media.In July 2020, the company unveiled the world's first lab-grown pork belly prototype and the second cell-based bacon (behind Mission Barns cell-based bacon unveiled in early 2020). The pork belly and the bacon were produced from a combination of cell-cultured muscle and plant-based proteins and fat. Uncommon plans to commercialize its cell-cultured meat by 2022-2025, pending regulatory approval.Funding and financialsIn <a href="https://sp-edge.com/updates/19267">June 2023</a>, the company raised USD 30 million in Series A funding co-led by Balderton Capital and Lower Carbon Capital, with participation from Redalpine, East Alpha, and others. The funds were earmarked for the development of its innovative approach, expanding production, increasing the team, and initiating regulatory approvals.

Uncommon

Multus, a spin-off of SOSV’s IndieBio program, is a biotechnology company that specializes in the development of growth media solutions for cellular agriculture applications. Its portfolio includes serum-free FBS alternatives (Proliferum M and Proliferum LSR) and solutions that support cell adhesion (rh-Vitronectin) during the cultivation process.Multus leverages MediOp, a growth media formulation design platform, to develop its solutions. According to the company, this technology allows optimizing solutions using automated data analysis and insights. Multus also uses this platform to provide contract manufacturing services for custom formulation design and food-safe manufacturing compliant with ISO22000 to customers in North America, Europe, and Asia-Pacific. In December 2024, the company launched&nbsp;<a href="https://sp-edge.com/updates/37120">Proliferum B</a>, an animal component-free alternative to fetal bovine serum (FBS) for cultivated meat production.In <a href="https://sp-edge.com/updates/25572">January 2024</a>, the company unveiled what it claims to be the first large-scale production plant-making serum-free growth media in the cultivated meat industry.Key customers and partnershipsIn <a href="https://sp-edge.com/updates/24911">December 2023</a>, the company partnered with New Wave Biotech, a bioprocess optimization software company, under a project funded through an Innovate UK Engineering Biology grant. Through this partnership, Multus planned to use New Wave Biotech’s AI software to optimize its process of developing precision-fermented ingredients for cell cultivation.&nbsp;

Multus

Based in Israel, Believer Meats (Future Meat Technologies prior to November 2022) develops hardware and cell lines for the manufacturing of cell-cultured meat, to commercialize its manufacturing hardware and techniques.Believer Meats uses fibroblast cells that can be triggered with small molecules to develop either fat or muscle cells. Fat and muscle cells are cultured in a unique bioreactor that removes the waste material from the media, allowing the company to recycle parts of the media to reduce feed media input by as much as 50%. The startup replaced FBS with molecules derived from Chinese hamster ovaries (CHO) to reduce production costs and plans to achieve price parity with animal counterparts.In <a href="https://sp-edge.com/updates/12623">August 2022</a>, the company announced it has developed what it claims to be the world’s first cultivated lamb, using cell lines isolated from Awassi sheep.In <a href="https://sp-edge.com/updates/15195">December 2022</a>, the company announced it has begun development of a 200,000 sq foot production facility in Wilson, North Carolina with an annual capacity of ~22 million lbs, which is claimed to be the largest cultivation facility in the world. Believer Meats plans to produce cultured chicken, pork, beef, and lamb for US, European, and Asian markets.Key customers and partnershipsIn March 2022, the company <a href="https://sp-edge.com/updates/9320">partnered</a> with Charoen Pokphand Foods to develop cultivated meat products for Asia.In <a href="https://sp-edge.com/updates/17710">April 2023</a>, Believer Meats signed an MoU with Archer Daniels Midland (ADM) to collaborate on the development and commercialization of cultivated meat products. Further, ADM will offer its ingredient pantry and nutrition knowledge to enhance Believer's cell-cultivated meat process.In <a href="https://sp-edge.com/updates/30520">June 2024,</a> Believer Meats partnered with Abu Dhabi’s AgriFood Growth &amp; Water Abundance (AGWA), to advance cultivated meat production in the MENA region.&nbsp;&nbsp;

Believer Meats

Producers of cell-cultured seafood using cells extracted from fish. Startups have succeeded in developing prototypes of yellowtail and salmon

Producers of cell-cultured pork using cells extracted from animals. Startups have succeeded in developing prototypes of bacon and pork belly using cultured muscle and plant-based proteins and fat

Producers of cell-cultured beef using cells extracted from animals. Some producers in the industry are developing premium beef ranges such as Wagyu. Startups have only succeeded in developing prototypes in the minced form, with a few creating prototypes of (pieces of) steak using 3D bioprinters

Producers of cell-cultured chicken and duck using cells extracted from animals. Some producers in the industry are developing rare delicacies such as foie gras. Startups have only succeeded in developing products in the nugget form

Producers of growth media for cell-cultured meat production and ingredients for meat and meat analog (cell-cultured, plant-based) producers, which can include cell culture meat paste, culture fat, etc. Producers of growth media mainly focus on developing alternative growth media to FBS using plant-based or other sources

Developers of bioreactors and other technologies used in cell-cultured meat production. Industrial scaling and efficiency gains are key areas of interest for startups in the industry

Provide sustainable solutions for animal slaughter through the use of biotechnology

PROMINENT_CATEGORY

<div>
 Unicorn Biotechnologies, a biotechnology startup from the UK, has recently introduced three new products via its Dragon Bio platform. In addition, they have secured a commercial partnership with another firm, QKine. The company has successfully developed a non-GMO, immortalized, cell line adapted for suspension, which is capable of producing pig fat.
 In enhancement to these achievements, Unicorn has also progressed in its research and development. They conducted benchmarking tests on their Emmet system, a technology designed to decrease labor and manufacturing costs and reduce process variability for those involved in cell culture research and manufacturing, with pluripotent stem cells being a particular focus. The firm has also filed three non-provisional patents with the US Patent and Trademark Office. Towards ensuring quality management and meeting international standards, Unicorn aims to acquire ISO 9001 accreditation and Good Manufacturing Practice certification over the course of the next year.
 
</div>

Unicorn Biotechnologies

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless